ISFIYA, Israel and BOSTON, MA, August, 10, 2017 -Check-Cap Ltd. (the "Company" or "Check-Cap") (NASDAQ: CHEK; CHEKW), a clinical-stage medical diagnostics company engaged in the development of C-Scan®, an ingestible capsule for preparation-free, colorectal cancer screening, today provided a corporate update and announced its financial results for the second quarter and six months ended June 30, 2017.

"During the recent quarter, we continued to advance our ongoing clinical program and are on track to submit C-Scan^® for CE Marking this summer," said Bill Densel, CEO of Check-Cap. "Following the achievement of the initial milestone of our ongoing collaboration, Check-Cap, along with our collaborator GE Healthcare, has received approval of a conditional grant to support a joint development project for C-Scan^® from the Israel-U.S. Binational Industrial Research and Development Foundation. This project aims to develop a high volume manufacturing and distribution process of C-Scan^® to the U.S. market."

Recent Highlights:

Check-Cap and GE Healthcare received approval of a $1 million conditional grant from the Israel-U.S. Binational Industrial Research and Development Foundation (BIRD). The grant will support development of a high-volume manufacturing process for the C-Scan^® system's X-ray source and capsule assembly, and establishing a unique product distribution process for a pilot clinical trial in the U.S. The award of the grant is conditioned, among other things, on submission of an application for CE Marking of the C-Scan^® system.

On June 2, 2017 the Company closed a registered direct offering of ordinary shares and a concurrent private placement with gross proceeds of $2.69 million with a single health-care focused institutional investor.

Financial Results for the Second Quarter Ended June 30, 2017

Research and development expenses, net were $2.0 million in the three months ended June 30, 2017, compared to $1.1 million in the same period in 2016. The increase is primarily attributable to (1) $561,000 grant received from the Israel Innovation Authority (the "IIA") which was credited to research and development expenses, net during the second quarter of 2016 and (2) $355,000 related primarily to the Company's clinical trial to support CE Marking for the C-Scan® system.

General and administrative expenses were $0.8 million in the three months ended June 30, 2017, compared to $0.9 million in the same period in 2016. The decrease was primarily due to a $190,000 decrease in share-based compensation, which was offset primarily by an increase in payroll related expenses ($103,000).

Operating loss was $2.8 million for the three months ended June 30, 2017, compared to $2.0 million in the same period in 2016.

Finance expenses, net were $20,000 in the three months ended June 30, 2017, compared to $15,000 in the same period in 2016.

Net loss was $2.8 million in the three months ended June 30, 2017, compared to $2.0 million in the same period in 2016.

Non-GAAP net loss was $2.7 million in the three months ended June 30, 2017, compared to $1.6 million in the same period in 2016.

Cash, cash equivalents and short-term bank deposit totaled $9.2 million at June 30, 2017, compared to $9.4 million at March 31, 2017. Check-Cap's cash balance as of June 30, 2017 includes the net proceeds from the June 2, 2017 registered direct offering and concurrent private placement.

Financial Results for the Six Months Ended June 30, 2017

Research and development expenses, net were $3.9 million in the six months ended June 30, 2017, compared to $2.9 million in the same period in 2016. The increase is primarily attributable to (1) $651,000 grant received from the IIA which was credited to research and development expenses, net during the six months ended June 30, 2016 and (2) $428,000 related primarily to the Company's clinical trial to support CE Marking for the C-Scan® system. This increase was partially offset by a $88,000 decrease in share-based compensation.

General and administrative expenses were $1.7 million in the six months ended June 30, 2017, compared to $2.0 million in the same period in 2016. The decrease was primarily due to a $360,000 decrease in share-based compensation, which was offset primarily by an increase in payroll related expenses ($69,000).

Operating loss was $5.6 million for the six months ended June 30, 2017, compared to $4.9 million in the same period in 2016.

Finance income, net was $90,000 in the six months ended June 30, 2017, compared to $143,000 in the same period in 2016.

Net loss was $5.5 million in the six months ended June 30, 2017, compared to $4.7 million in the same period in 2016.

Non-GAAP net loss was $5.1 million in the six months ended June 30, 2017, compared to $4.0 million in the same period in 2016.

Net cash used in operating activities was $5.0 million in the six months ended June 30, 2017, compared to $4.8 million in the same period in 2016.

A reconciliation of GAAP results to non-GAAP results is provided below.

The number of outstanding ordinary shares as of June 30, 2017, was 16,979,845, this number includes the 1,349,500 ordinary shares that were issued in the June 2, 2017 registered direct offering.

Use of Non-GAAP Financial Results

In addition to disclosing financial results calculated in accordance with U.S. GAAP, the Company's financial results release contains Non-GAAP financial measures of net loss for the period that exclude the effects of share-based compensation and changes in royalties provision. The Company's management believes the Non-GAAP financial information provided in this release is useful to investors' understanding and assessment of the Company's on-going operations. Management also uses both GAAP and Non-GAAP information in evaluating and operating business internally and as such deemed it important to provide all this information to investors. The Non-GAAP financial measures disclosed by the Company should not be considered in isolation or as a substitute for, or superior to, financial measures calculated in accordance with GAAP, and the financial results calculated in accordance with GAAP and reconciliations to those financial statements should be carefully evaluated. Reconciliations between GAAP measures and Non-GAAP measures are provided later in this press release.

About Check-Cap

Check-Cap is a clinical-stage medical diagnostics company developing C-Scan®, the first capsule-based system for preparation-free colorectal cancer screening.

Utilizing innovative ultra-low dose X-ray and wireless communication technologies, the capsule generates information on the contours of the inside of the colon as it passes naturally. This information is used to create a 3D map of the colon, which allows physicians to look for polyps and other abnormalities. Designed to improve the patient experience and increase the willingness of individuals to participate in recommended colorectal cancer screening, C-Scan® removes many frequently-cited barriers, such as laxative bowel preparation, invasiveness and sedation. The C-Scan® system is currently not cleared for marketing in any jurisdiction.

Legal Notice Regarding Forward-Looking Statements

This press release contains "forward-looking statements." Words such as "may," "should," "could," "would," "predicts," "potential," "continue," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates," and similar expressions, as well as statements in future tense, often signify forward-looking statements. Forward-looking statements should not be read as a guarantee of future performance or results and may not be accurate indications of when such performance or results will be achieved. Forward-looking statements are based on information that the Company has when those statements are made or management's good faith belief as of that time with respect to future events, and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements. For a discussion of these and other risks that could cause such differences and that may affect the realization of forward-looking statements, please refer to the "Special Note On Forward-looking Statements" and "Risk Factors" in the Company's Annual Report on Form 20-F and other filings with the Securities and Exchange Commission (SEC). Investors and security holders are urged to read these documents free of charge on the SEC's web site at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.

	June 30,			December 31,
	2017			2016
Assets
Current assets
Cash and cash equivalents		9,152			11,639
Prepaid expenses and other current assets		424			242
Total current assets		9,576			11,881

Non-current assets
Property and equipment, net		526			414
Total non-current assets		526			414
Total assets		10,102			12,295

Liabilities and shareholders' equity
Current liabilities
Accounts payable and accruals
Trade		549			393
Other		389			235
Other current liabilities		11			11
Employees and payroll accruals		951			728
Total current liabilities		1,900			1,367

Non-current liabilities
Royalties provision		570			521
Total non-current liabilities		570			521

Shareholders' equity
Share capital		861			771
Additional paid-in capital		55,198			52,577
Accumulated deficit		(48,427	)		(42,941	)
Total shareholders' equity		7,632			10,407

Total liabilities and shareholders' equity		10,102			12,295

	Six months ended June 30,				Three months ended June 30,
	2017		2016		2017			2016

Research and development expenses, net		3,874		2,883		1,997			1,081
General and administrative expenses		1,696		1,992		810			894
Operating loss		5,570		4,875		2,807			1,975

Finance income (expenses), net		90		143		(20	)		(15	)
Loss before tax		5,480		4,732		2,827			1,990
Taxes on income		6		-		3			-
Net loss for the period		5,486		4,732		2,830			1,990

Net loss per ordinary share basic and diluted		0.33		0.36		0.17			0.15

Weighted average number of ordinary shares outstanding - basic and diluted (in thousands)		16,635		13,277		16,840			13,274

	Six months ended June 30,
	2017			2016
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss for the period		(5,486	)		(4,732	)
Depreciation and amortization		73			63
Share-based compensation		347			794
Financial income, net		(158	)		(64	)
Changes in assets and liabilities items:
Decrease in prepaid and other current assets and non-current assets		(182	)		(219	)
Increase (decrease) in trade accounts payable, accruals and other current liabilities		107			(93	)
Increase (decrease) in employees and payroll accruals		223			(535	)
Increase (decrease) in royalties provision		49			(13	)
Net cash used in operating activities		(5,027	)		(4,799	)

CASH FLOWS FROM INVESTING ACTIVITIES
Purchase of property and equipment		(81	)		(79	)
Decrease in restricted deposit		-			46
Proceeds from short-term investments		-			3,811
Net cash provided by (used in) investing activities		(81	)		3,778

CASH FLOWS FROM FINANCING ACTIVITIES
Exercise of warrants into ordinary shares		82			5
Issuance of ordinary shares in RD 2017, net of issuance expenses in an amount of $349		2,380			-
Net cash provided by financing activities		2,462			5

Effect of exchange rate changes on cash and cash equivalents		159			61
Net decrease in cash and cash equivalents		(2,487	)		(955	)
Cash and cash equivalents at the beginning of the period		11,639			9,392
Cash and cash equivalents at the end of the period		9,152			8,437

	Six months ended June 30,						Three months ended June 30,
	2017			2016			2017			2016

GAAP net loss for the period		(5,486	)		(4,732	)		(2,830	)		(1,990	)
Share-based compensation (1)		347			794			133			358
Changes in royalties		49			(13	)		25			11
Non-GAAP net loss for the period		(5,090	)		(3,951	)		(2,672	)		(1,621	)

(1) Share-based compensation:
Research and development expenses, net		75			162			31			66
General and administrative expenses		272			632			102			292
		347			794			133			358